ABOUT US
Mark Zamoyski, Founder and Chairman
Mark Zamoyski is the founder, primary investor, and the principal scientist. Mark has spent the last several years on innovative solutions for unmet medical needs. Mark's issued patents include novel antiviral, anti-inflammatory, and antiproliferative compounds for use in dermal and pulmonary indications. Dermal conditions targeted include psoriasis, herpes lesions, acne, and cosmetic and medical epidermal exfoliation. Pulmonary conditions include lung neoplasms, COPD, Avian flu, and inflammation.
Mark also has issued patents for improved oncology protocols when using compounds such as HER blockers, anti-endocrines, or S-Phase cytotoxics and a patent is pending for protocols for improved outcome when dealing with cancers that have metastasized to bone.
Mark also has a patent pending disclosing novel etiology and novel treatment methods related to premenstrual headaches and migraines.
Prior to NexGen, Mark spent 12 years with Biomation Corporation and its parent company, where he worked his way up to executive positions including CFO and VP of Sales and Marketing and was involved in the ultimate sale of the company. Mark received his BS in 1977 and MBA in 1978, both from Cornell University.
Dr. Maria Zagorski, MD, - Advisory Board
Dr. Maria Zagorski received her MD from George Washington School of Medicine in 1979 and her bachelors degree in Biochemistry with distinction in all subjects in 1975 from Cornell University. She did her internship and residency at UCLA Hospital. She founded, managed, and sold three medical corporations (Valencia Gynecology, Zagorski Medical Group, and Van Nuys Urology).
She provides guidance from both a molecular medicine perspective and from a practitioner’s perspective.
Dr. Radomir Julina, Ph.D., - Advisory Board
Dr. Julina has unique expertise with virtual drug development, having structured and managed accelerated drug development, using efficient “multi-company” entities and global outsourcing. Dr. Julina was Co-Founder and Director of Protodigm Ltd. (UK), an innovative virtual drug development company based on outsourcing, which was spun out of Roche.
Dr. Julina spent 15 years with Hoffman-LaRoche in Switzerland, USA and UK where he worked primarily in pharma operations and drug development. He was directly involved in the global development of a number of therapeutic products by taking them from IND to the marketplace. He was instrumental in the development of drugs including Xeloda (cancer) and Xenical (obesity). Dr. Julina was also Co-Founder and former Head of R&D and Vice-Chairman of CarboGen Laboratories and CEO of Pharmaceutix Inc.
Dr. Julina also has investor side experience. He was involved in the management of a later stage investment fund (Celtic Pharma) whose investments include Xenova (brain cancer) and IDEA AG (transdermal liposomal delivery).
Dr. Ving J. Lee Ph.D., - Advisory Board
Dr. Lee has expertise in accelerated drug discovery and pre-clinical research using integrated chemistry and systems biology. He has extensive experience with anti-infectives, having been involved in the discovery and / or development of mitoxantrone (Wyeth), bisantrene, tazobactam (Wyeth), cefixime, cefuzonam, beta-lactamase inhibitors, the glycylcyclines, gyrase inhibitors, oral carbapenems, beta-lactams for problematic gram-positive pathogens, uridyl-peptide antibiotics, inhibitors of bacterial efflux pumps, and antiviral agents. Dr. Lee also has working knowledge of various natural products and fungal mycotoxins, including our molecules, and extensive contacts in pharmaceutical companies and government agencies involved with anti-infectives. Dr. Lee's career includes positions with Anacor Pharmaceuticals, Microcide Pharmaceuticals, and Lederle. While at Anacor, Dr. Lee raised $ 30 M, of which $ 7 M was VC funding and $ 23 M was government funding.
Dr. Lee is currently CEO and CSO for Adesis Inc., a chemistry based CRO whose customer base ranges from small biotechs to Big Pharma. Dr. Lee is also SAB member at Micrologix Biotech (Vancouver), Chiralogix Pharmaceuticals (Vancouver), Ulysses Pharmaceuticals (Montreal), BioSource (New York), Green Hill Biotechnology (Austria); BOD member for CB Research and Development.
© 2003 - 2008 Mark Zamoyski & NexGen Biomedical, Inc.